Physician profile
Chi-Whei Lin
NPI 1114057254
$2,327.62
in general payments reported to CMS, 2019-2025
19 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $415 · 2021: $400 · 2022: $244 · 2023: $269 · 2024: $368 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $953.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $415.48 | 2019-2025 | Veozah |
| Revance Therapeutics, INC. | $384.29 | 2024-2025 | Daxxify |
| Glaxosmithkline, LLC. | $284.22 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $277.67 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.27 | 2020-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $193.42 | 2021-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.95 | 2021-2023 | Xifaxan |
| Pfizer INC. | $87.39 | 2022-2025 | |
| Exact Sciences Corporation | $66.14 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $47.05 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $28.19 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.07 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.80 | 2022 | |
| Novo Nordisk INC | $24.39 | 2020 | |
| Eisai INC. | $18.73 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.45 | 2023 | Otezla, Repatha |
| Sanofi Pasteur INC. | $18.42 | 2023 | |
| Lilly USA, LLC | $17.80 | 2025 | Kisunla |
| Lucid Diagnostics INC. | $16.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chi-Whei Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.